Skip to main content

Market Overview

Last Night's Election - A Series Of Fortunate Events For Big Pharma

Last Night's Election - A Series Of Fortunate Events For Big Pharma

Pharmaceutical investors could breathe a sigh of relief after Donald Trump won the race to the White House, at least according to Alex Arfaei of BMO Capital Markets.

Arfaei commented in a research report on Wednesday that a Trump presidency, coupled with a Republican Congress and the apparent defeat of Proposition 61 in California are all factors that support the pharmaceutical industry.

Arfaei continued that the pharmaceutical space will be characterized by the following:

  1. Lower drug pricing pressures.
  2. The potential repeal of the Affordable Care Act ("Obamacare") with more industry friendly reforms.
  3. Increased probability of lower corporate tax rates.
  4. Profit repatriation.

Drug Pricing Pressures

Hillary Clinton campaigned on targeting drug prices, but her defeat in the election now makes her proposals much less likely.


Trump campaigned to repeal Obamacare and replace it with reforms that follow free market principles.

While the Republicans may or may not be successful in actually repealing Obamacare — and it is uncertain what it would be replaced with — chances are likely it will be replaced with reforms that are friendly to the pharmaceutical industry.

Corporate Tax Rates

The analyst views Trump's plans to lower corporate tax rates from 35 percent to 15 percent as being favorable for the pharmaceutical industry. In addition, Trump's proposals of allowing companies to repatriate foreign cash at a one-time 10 percent tax rate will result in increased capital returns to shareholders through dividends and share buybacks.

Top Pick

Arfaei concluded that the U.S. election should be viewed as positive for the entire pharmaceutical universe, particularly for Pfizer Inc. (NYSE: PFE).

At Last Check ...

  • iShares Dow Jones US Pharm Indx (ETF) (NYSE: IHE) was up 5.5 percent at $143.29.
  • iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is up 7.47 percent at $281.16.
  • Pfizer was up 6.33 percent at $31.90.
  • SPDR S&P Biotech (ETF) (NYSE: XBI) was up 8.31 percent at $62.59.
  • SPDR S&P Pharmaceuticals (ETF) (NYSE: XPH) was up 5.31 percent at $40.23.

Latest Ratings for PFE

May 2021Morgan StanleyMaintainsEqual-Weight
May 2021MizuhoDowngradesBuyNeutral
May 2021SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings


Related Articles (XPH + PFE)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Specialty ETFs Health Care Politics Legal Analyst Ratings Best of Benzinga

Latest Ratings

EMNGoldman SachsUpgrades148.0
DDGoldman SachsUpgrades102.0
HUNGoldman SachsDowngrades33.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at